INO
Inovio Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Buy"
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INO
Inovio Pharmaceuticals, Inc.
A biotechnology company that developing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV
660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462
--
Inovio Pharmaceuticals, Inc., was originally established on June 29, 1983, and is registered under the laws of the State of California as a biotechnology laboratory company. The company is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. The company's platform leverages the power of protein production in the body, featuring the optimized design and delivery of DNA drugs, to teach the body to create disease-fighting tools.
Earnings Call
Q1/2025
Estimate EPS-0.74
Actual EPS-0.51
Estimate Revenue10.00K
Actual Revenue65.34K
Inovio's Q1 2025: Key Contradictions in Clinical Benefits, Manufacturing Delays, and Regulatory Strategies
May 20,2025 02:19
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.62
Actual EPS-0.61
Estimate Revenue8.33K
Actual Revenue0
Inovio’s 2025Q2 Earnings Call: Key Contradictions on Regulatory Strategy, Financial Health, and Clinical Trials
Aug 13,2025 03:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
INO has released its 2025 Q3 earnings. EPS was reported at -0.87, versus the expected -0.48, missing expectations. The chart below visualizes how INO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
